Valneva Reports Positive Shigella Vaccine Phase 2 Results
Two Phase 2 trials of the S4V2 candidate showed a favorable safety profile and immune response against Shigella.
Updated on Nov. 9, 2026 in Diseases — General

Live Poll
Should governments prioritize funding for vaccines against deadly childhood diseases?
Valneva SE announced positive results from two Phase 2 trials of its Shigella4V2 (S4V2) vaccine candidate. The company is now evaluating the complete dataset to determine the next path forward for the candidate.
Why it matters
There is currently no licensed vaccine to prevent shigellosis, a diarrheal disease that causes significant illness and death worldwide. Positive Phase 2 data for S4V2 supports continued development of a potential first-in-class option.
The infant trial in Kenya enrolled 110 nine-month-old infants and the CHIM trial enrolled roughly 120 healthy adults aged 18 to 50 across three U.S. sites, with the CHIM trial meeting its primary endpoint against placebo. Further efficacy and immunogenicity analysis is still ongoing, and the complete dataset is under evaluation.
The players
Valneva SE
Valneva is a French vaccine company based in Lyon, France, that develops vaccines for infectious diseases including the S4V2 Shigella candidate.
LimmaTech
LimmaTech is a biotechnology company that sponsored both Phase 2 trials of the S4V2 vaccine candidate.
Gates Foundation
The Gates Foundation is a major philanthropic organization that supported funding for the S4V02 infant trial.
The details
Valneva reported that S4V2 showed a favorable safety and tolerability profile across both dose levels in the infant trial, and induced significant antibody increases for all four targeted Shigella serotypes. In the adult CHIM trial, participants received two doses one month apart before challenge with the Shigella sonnei 53G strain, and the vaccine reduced shigellosis versus placebo.
Timeline
2024: The FDA granted Fast Track designation to S4V2.
November 9, 2026: Valneva announced the positive Phase 2 results.
Health Landscape
Shigellosis has no licensed vaccine, leaving a gap that candidates like S4V2 aim to fill after the FDA granted it Fast Track designation in 2024. The positive Phase 2 data advances a candidate in a field where prevention has long lagged behind treatment for this diarrheal disease.
For travelers and families in regions where shigellosis is common, a licensed vaccine would offer a new prevention option once one is approved. The vaccine remains in clinical development, so no preventive product is available to the public yet.
The takeaway
Shigellosis is a major cause of diarrheal illness and death, particularly among young children in low- and middle-income countries. Continued vaccine development, like the S4V2 program, is the main path toward prevention, while handwashing and safe water remain the practical defenses available today.
Further reading
Explore more on Diseases — General for background on infections like shigellosis.
Live Poll
Should governments prioritize funding for vaccines against deadly childhood diseases?



